DelveInsight’s, “Psoriatic Arthritis Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Psoriatic Arthritis pipeline landscape. It covers the Psoriatic Arthritis pipeline drug profiles, including Psoriatic Arthritis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Psoriatic Arthritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Psoriatic Arthritis NDA approvals (if any), and product development activities comprising the technology, Psoriatic Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Psoriatic Arthritis Pipeline Report
To explore more information on the latest breakthroughs in the Psoriatic Arthritis Pipeline treatment landscape of the report, click here @ Psoriatic Arthritis Pipeline Outlook
Psoriatic Arthritis Overview
Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling. Psoriatic arthritis is considered as seronegative spondyloarthropathies.
Recent Developments Activities in the Psoriatic Arthritis Treatment Landscape
For further information, refer to the detailed Psoriatic Arthritis Unmet Needs, Psoriatic Arthritis Market Drivers, and Psoriatic Arthritis Market Barriers, click here for Psoriatic Arthritis Ongoing Clinical Trial Analysis
Psoriatic Arthritis Emerging Drugs Profile
Discovered and developed by AbbVie, RINVOQ is a selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases. In August 2019, RINVOQ received U.S. Food and Drug Administration approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, RINVOQ also received approval by the European Commission for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Phase 3 trials of RINVOQ in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Crohn’s disease, atopic dermatitis, ulcerative colitis and giant cell arteritis are ongoing.
Risankizumab is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases, including psoriasis.
Psoriatic Arthritis Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Psoriatic Arthritis. The companies which have their Psoriatic Arthritis drug candidates in the most advanced stage, i.e. Registered include, Abbvie.
Request a sample and discover the recent advances in Psoriatic Arthritis Ongoing Clinical Trial Analysis and Medications, click here @ Psoriatic Arthritis Treatment Landscape
Scope of the Psoriatic Arthritis Pipeline Insight Report
Dive deep into rich insights for drugs for Psoriatic Arthritis Market Drivers and Psoriatic Arthritis Market Barriers, click here @ Psoriatic Arthritis Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Psoriatic Arthritis Mergers and acquisitions, Psoriatic Arthritis Licensing Activities @ Psoriatic Arthritis Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/